XLO (Xilio Therapeutics, Inc. Common Stock) Stock Analysis - News
Xilio Therapeutics, Inc. Common Stock (XLO) is a publicly traded Healthcare sector company. As of May 21, 2026, XLO trades at $8.44 with a market cap of $48.76M and a P/E ratio of -1.97. XLO moved +1.83% today. Year to date, XLO is -10.87%; over the trailing twelve months it is -32.88%. Its 52-week range spans $6.47 to $23.80. Rallies surfaces XLO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in XLO news today?
Xilio Therapeutics Extends Runway to 2028, Plans XTX501 IND in Mid-2026: Xilio Therapeutics ended Q1 2026 with $150.3 million cash, extended runway into early 2028 after a $6.0 million development milestone under its AbbVie collaboration. The company plans IND submission for its bispecific PD-1/masked IL-2 candidate XTX501 in mid-2026 and Phase 1 initiation in the second half of 2026, while advancing masked T cell engager programs with new preclinical data for XTX601.
Shannon James Samuel bought 5.00K (~$43.95K) on Mar 26, 2026.
Brennan Kevin M. sold 1.83K (~$1.17K) on Jan 2, 2026.
Frankenfield Christopher James sold 7.03K (~$4.52K) on Jan 2, 2026.
XLO Analyst Consensus
XLO analyst coverage data. Average price target: $0.00.
Common questions about XLO
What changed in XLO news today?
Xilio Therapeutics Extends Runway to 2028, Plans XTX501 IND in Mid-2026: Xilio Therapeutics ended Q1 2026 with $150.3 million cash, extended runway into early 2028 after a $6.0 million development milestone under its AbbVie collaboration. The company plans IND submission for its bispecific PD-1/masked IL-2 candidate XTX501 in mid-2026 and Phase 1 initiation in the second half of 2026, while advancing masked T cell engager programs with new preclinical data for XTX601.
Does Rallies summarize XLO news?
Yes. Rallies summarizes XLO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is XLO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XLO. It does not provide personalized investment advice.
